On Jan. 29, 2021, Johnson & Johnson announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrated that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary andkey secondary endpoints.

The topline safety and efficacy data were based on 43,783participants accruing 468 symptomatic cases of COVID-19.